Attached files
| file | filename |
|---|---|
| EX-10.1 - Echo Therapeutics, Inc. | ex10-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 31, 2015
Echo Therapeutics, Inc.
(Exact name of Company as specified in its charter)
|
Delaware
|
001-35218
|
41-1649949
|
||
|
(State or other jurisdiction
of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
||
|
99 Wood Avenue South., Suite 302
Iselin, NJ
|
08830
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Company’s telephone number, including area code: (732) 549-0128
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 2.03
|
Creation of a Direct Financial Obligation or an Obligation Under an Off- Balance Sheet Arrangement of a Registrant.
|
On December 31, 2015, Echo Therapeutics, Inc. (the “Company”) issued a promissory note to Platinum Partners Value Arbitrage Fund, L.P. in the aggregate principal amount of $150,000. The Company also issued a promissory note to each of Beijing Yi Tang Bio Science & Technology, Ltd. in the aggregate principal amount of $80,000 and Medical Technologies Innovation Asia, Ltd. in the aggregate principal amount of $100.000, in each case, in respect of funds previously received by the Company from such parties. The promissory notes, which bear interest at the prime rate, are due on the earlier of the consummation of certain financings or thirty days after the date thereof. The noteholders maintain an exchange right into certain future financings.
The description of the promissory notes set forth herein does not purport to be complete and is qualified in its entirety by reference to the form of promissory note, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
10.1 Form of Promissory Note
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ECHO THERAPEUTICS, INC.
|
||
|
Dated: January 6, 2016
|
By: /s/ Alan W. Schoenbart
|
|
|
Alan W. Schoenbart
|
||
|
Chief Financial Officer
|
||